Loading...
 
Translate Register Log In Login with facebookLogin and Register

Vitamin D levels of HIV and non HIV equally restored with 50,000 IU twice a week - July 2015

Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection

Open Forum Infect Dis (Spring 2015) 2 (2): doi: 10.1093/ofid/ofv068
Jordan E. Lake1, Risa M. Hoffman1, Chi-Hong Tseng1, Holly M. Wilhalme1, John S. Adams2 and Judith S. Currier1
1Department of Medicine
2Department of Orthopaedic Surgery, University of California, Los Angeles
Correspondence: Jordan E. Lake, MD, MSc, UCLA Department of Medicine, Center for Clinical AIDS Research and Education, 11075 Santa Monica Blvd., Ste. 100, Los Angeles, CA 90025 (jlake@mednet.ucla.edu).
Presented in part: 13th International Workshop on Adverse Drug Reactions and Co-Morbidities in Rome, Italy.
Image
Background. Vitamin D insufficiency is prevalent in human immunodeficiency virus-positive (HIV+) persons. Human immunodeficiency virus and antiretroviral therapy (ART) may create unique risk factors, and the optimal vitamin D repletion and maintenance regimen in HIV+ persons remains unclear.

Methods. Human immunodeficiency virus-positive adults on suppressive ART underwent routine serum 25-hydroxyvitamin D (25OHD) screening. Persons with vitamin D insufficiency (25OHD <30 ng/mL) received open-label, oral vitamin D3 50 000 international units (IU) twice weekly for 5 weeks, then 2000 IU daily to complete 12 weeks. We predicted 70% (95% confidence interval, 60%–80%) repletion to 25OHD ≥30 ng/mL compared with 85% among historical HIV-negative controls. Eighty participants provided 91% power to detect this difference. Ability to maintain 25OHD ≥30 ng/mL after 24 weeks was also assessed.

Results. Baseline characteristics were similar between the 82 vitamin D insufficient and 40 sufficient persons enrolled: 95% male, 60% white, 88% nonsmokers, median age 49 years, body mass index 26 kg/m2, and CD4+ T lymphocyte count 520 cells/mm3. After 12 weeks, 81% (66 of 82) of insufficient persons achieved 25OHD ≥30 ng/mL (P = .32 vs historical controls), with only older age (odds ratio [OR] = 1.06; P = .06), higher baseline 25OHD (OR = 1.14; P < .01), white race (OR = 3.39; P = .04), and current smoking (OR = 0.25; P = .06) associated with successful repletion. After 24 weeks, 73% (48 of 66) maintained 25OHD ≥30 ng/mL, with tenofovir (OR = 5.00; P = .01) and abacavir use (OR = 0.23; P = .02) associated with success and failure, respectively, to maintain 25OHD levels.

Conclusions. The 25OHD repletion rates were comparable between HIV+ adults on suppressive ART and historical HIV-negative controls, indicating that successful oral repletion can be achieved in this population.

 Download the PDF from VitaminDWiki


See also VitaminDWiki

Attached files

ID Name Comment Uploaded Size Downloads
5719 50000 response.jpg admin 24 Jul, 2015 09:53 23.14 Kb 925
5718 HIV repleation.pdf PDF 2015 admin 24 Jul, 2015 09:48 180.66 Kb 406
See any problem with this page? Report it (FINALLY WORKS)